Dong-A Socio Holdings Co., Ltd. (KRX:000640)

Market Cap	717.58B
Revenue (ttm)	1.36T
Net Income (ttm)	68.06B
Shares Out	6.44M
EPS (ttm)	10,569.35
PE Ratio	10.55
Forward PE	7.72
Dividend	1,650.49 (1.48%)
Ex-Dividend Date	Jun 27, 2025

Volume	11,111
Average Volume	19,451
Open	110,600
Previous Close	110,500
Day's Range	110,500 - 112,000
52-Week Range	90,583 - 124,757
Beta	0.04
RSI	47.63
Earnings Date	Jul 29, 2025

About Dong-A Socio Holdings

Dong-A Socio Holdings Co., Ltd., together with its subsidiaries, engages in the pharmaceutical business in South Korea. It operates through Holding Company; Over-the-Counter Drugs and Quai-Drugs; Biosimilars and Consignment Medicines; Logistics; Packaging Solutions; and Others segments. The company develops DA-8010 in Phase 3 clinical trial to treat overactive bladder; DMB-3115, a biosimilar of Stelara in Phase 3 clinical trial; DA-1241 in Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis; DA-1726 in Phase 1 clinical tri...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1932
• Employees: 5,530
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 000640

Financial Performance

In 2024, Dong-A Socio Holdings's revenue was 1.33 trillion, an increase of 17.78% compared to the previous year's 1.13 trillion. Earnings were 58.02 billion, an increase of 0.06%.